Official Recognition: PANS Joins PANDAS on the NIH Rare Disease List

Big news for our community! We are thrilled to share that the Genetic and Rare Diseases Information Center (GARD), which is managed by the National Institutes of Health (NIH), has officially added Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) to its list of rare diseases.

If you’ve been in this fight for a while, you know how much this matters. For years, PANDAS has been listed on the GARD site, but PANS: the broader umbrella that captures so many of our children’s experiences: was missing. Now, that gap has been closed. This isn’t just another page on a website; it is a major milestone in federal recognition.

The Missing Piece: Closing the Gap Between PANS and PANDAS

While PANS and PANDAS share the same hallmark abrupt onset of symptoms, such as OCD, the initial infectious trigger is what sets them apart. According to the PANS/PANDAS Research Consortium’s consensus guidelines, PANDAS is exclusively triggered by Group A Streptococcal (GAS) infections. In contrast, PANS has a broader, more complex etiology and can be caused by various other infections—such as the flu, walking pneumonia, or even environmental stressors.

By officially adding the PANS GARD page, the NIH is acknowledging the broader spectrum of these neuroimmune conditions. This ensures that when a parent or a pediatrician searches for answers to a child’s sudden, overnight personality change, they find accurate, federally-backed information.

Additionally, the Mondo Disease Ontology (MONDO) has also updated its records to reflect these changes, ensuring that global clinical and genomic databases are aligned. You can view the updated definitions on the Monarch Initiative pages for PANS and PANDAS.

Why This is a Turning Point for Families

If you are a parent who has been told your child’s symptoms are “just anxiety” or that you are “overreacting,” this news is for you. Official recognition by a body as prestigious as the NIH provides a powerful shield against medical gaslighting.

When a disease is listed on GARD, it carries the weight of the federal government. It means:

• Validation: You can point to an official government resource that describes exactly what your child is going through.
• Education: Primary care physicians, who may not be familiar with these conditions, can be provided GARD resources, along with a trusted repository for diagnostic guidance from PACE’s network of multidisciplinary clinics.
• Urgency: The GARD page highlights that on average, it can take over six years to receive a rare disease diagnosis. By listing PANS, we are working to shorten that window and get children back to their baseline faster.

The PACE Foundation’s Role in This Milestone

This update didn’t happen by accident. The PACE Foundation team worked directly with the dedicated professionals at GARD to ensure the information on the new PANS page was included in the most recent website updates.

We provided the latest research data and clinical insights to help GARD build a resource that truly serves the public. At PACE, our mission has always been to standardize diagnostic protocols and build a national network of specialized clinics. Seeing PANS recognized at this level is a testament to the advocacy work we do every day: work that is only possible because of our donors and partners.

Impact on Research, Funding, and Orphan Drug Designation

For our donors and pharmaceutical partners, this recognition has significant practical implications. In the world of medical research, “Rare Disease” status is a key that unlocks many doors.

1. Securing Orphan Drug Designation

To qualify for Orphan Drug Designation, a condition must affect fewer than 200,000 people in the United States. While PANS/PANDAS is more common than many realize, it still falls under this rare disease threshold. Having PANS officially listed on GARD provides a critical foundation for researchers applying for this designation. This status offers tax credits for clinical trials and potential market exclusivity, which are massive incentives for pharmaceutical companies to develop new, targeted treatments.

2. Boosting Research ROI

When a rare disease is federally recognized, it becomes easier to secure NIH grants and private philanthropic funding. For high-net-worth donors, this listing provides a layer of “proof of concept” for their investment. It shows that the field is moving toward the mainstream, and that their contributions are helping to build the infrastructure for a permanent, nationwide solution.

3. Advancing Clinical Protocols

The GARD page mentions the importance of multidisciplinary care centers. This is exactly what PACE has been advocating for: clinics where neurologists, immunologists, and psychiatrists work together. Federal recognition helps us push for these clinical pathways to become the standard of care in university hospitals across the country.

Actionable Steps for Parents and Providers

Now that the information is live, here is how you can use these new resources:

• For Parents: If you are navigating a new diagnosis or trying to convince a school or doctor that PANS is “real,” share the official GARD PANS link. Use it as a tool to open doors to better care.
• For Clinicians: Visit our Educational Resources page for the most up to date research and a pamphlet from the University of Arizona that breaks down diagnostic and treatment protocols. You can also visit our Clinics Page to find specialized centers for referral.
• For the Community: This is a victory, but the work isn’t done. We still need more research, more trained doctors, and more accessible treatments.

A Compassionate Path Forward

We know the road to a PANS/PANDAS diagnosis is often paved with heartbreak and exhaustion. We know what it feels like to watch your child disappear behind a wall of symptoms. But today, we celebrate a moment of clarity and recognition. The NIH has said, clearly and officially: We see you. This disease is real. And it belongs on the map of modern medicine.

The PACE Foundation remains committed to being your partner in this journey. Whether you are looking for patient resources or want to stay updated on the latest clinical trials, we are here for you.

Join the Movement

If you want to support our ongoing work to advocate for federal recognition and clinical excellence, here is how you can help:

• Sign up for our newsletter to stay updated on the latest PANS/PANDAS news.
• Donate to PACE to help us continue our work with organizations like GARD and fund life-changing research.
• Share your story to help us put a face to the rare disease listing.

Together, we are making sure that no child has to face PANS or PANDAS alone.